Retention of CD34(+) CML stem/progenitor cells during imatinib treatment and rapid decline after treatment with second-generation BCR–ABL inhibitors

Documenti analoghi

• Retention but significant reduction of BCR-ABL transcript in hematopoietic stem cells in chronic myelogenous leukemia after imatinib therapy
  di: Abe, Akihiro, et al.
  Pubblicazione: (2008)
• AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells
  di: Zhou, Liang L., et al.
  Pubblicazione: (2008)
• Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment
  di: Oaxaca, Derrick M., et al.
  Pubblicazione: (2016)
• Bcr-Abl Tyrosine Kinase Inhibitors in the Treatment of Pediatric CML
  di: Carofiglio, Francesca, et al.
  Pubblicazione: (2020)
• Beneficial effects of combining a Type II ATP competitive inhibitor with an allosteric competitive inhibitor of Bcr-Abl for the treatment of imatinib-sensitive and imatinib resistant CML
  di: Weisberg, Ellen, et al.
  Pubblicazione: (2010)